These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 19308043

  • 21. Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques.
    Farese AM, Yang BB, Roskos L, Stead RB, MacVittie TJ.
    Bone Marrow Transplant; 2003 Aug; 32(4):399-404. PubMed ID: 12900776
    [Abstract] [Full Text] [Related]

  • 22. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation.
    Staber PB, Holub R, Linkesch W, Schmidt H, Neumeister P.
    Bone Marrow Transplant; 2005 May; 35(9):889-93. PubMed ID: 15765110
    [Abstract] [Full Text] [Related]

  • 23. Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma.
    Ding X, Huang W, Peng Y, Fan H, Zhu Y, Liu X, Yang Y, Guo Q, Qiu L, Dai Y, Zou D, Jin F.
    Ann Hematol; 2020 Jun; 99(6):1331-1339. PubMed ID: 32382775
    [Abstract] [Full Text] [Related]

  • 24. Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours.
    Willis F, Woll P, Theti D, Jamali H, Bacon P, Baker N, Pettengell R.
    Bone Marrow Transplant; 2009 Jun; 43(12):927-34. PubMed ID: 19169289
    [Abstract] [Full Text] [Related]

  • 25. Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas.
    Ballestrero A, Boy D, Gonella R, Miglino M, Clavio M, Barbero V, Nencioni A, Gobbi M, Patrone F.
    Ann Hematol; 2008 Jan; 87(1):49-55. PubMed ID: 17710398
    [Abstract] [Full Text] [Related]

  • 26. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
    Nakasone H, Kanda Y, Ueda T, Matsumoto K, Shimizu N, Minami J, Sakai R, Hagihara M, Yokota A, Oshima K, Tsukada Y, Tachibana T, Nakaseko C, Fujisawa S, Yano S, Fujita H, Takahashi S, Kanamori H, Okamoto S, Kanto Study Group of Cell Therapy.
    Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
    [Abstract] [Full Text] [Related]

  • 27. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
    Skopec B, Skerget M, Zontar D, Zadnik V, Zver S.
    Wien Klin Wochenschr; 2017 Aug; 129(15-16):545-551. PubMed ID: 28439700
    [Abstract] [Full Text] [Related]

  • 28. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies.
    Putkonen M, Rauhala A, Pelliniemi TT, Remes K.
    Ann Hematol; 2009 Jul; 88(7):673-80. PubMed ID: 19139894
    [Abstract] [Full Text] [Related]

  • 29. Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?
    Merlin E, Zohar S, Jérôme C, Veyrat-Masson R, Marceau G, Paillard C, Auvrignon A, Le Moine P, Gandemer V, Sapin V, Halle P, Boiret-Dupré N, Chevret S, Deméocq F, Dubray C, Kanold J.
    Bone Marrow Transplant; 2009 Jun; 43(12):919-25. PubMed ID: 19104490
    [Abstract] [Full Text] [Related]

  • 30. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.
    Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL, Chen H, Schuening FG.
    Bone Marrow Transplant; 2005 Jun; 35(12):1165-9. PubMed ID: 15880129
    [Abstract] [Full Text] [Related]

  • 31. A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy.
    Bassi S, Rabascio C, Nassi L, Steffanoni S, Babic A, Bertazzoni P, Gigli F, Antoniotti P, Orlando L, Sammassimo S, Quarna J, Negri M, Martinelli G.
    Transfus Apher Sci; 2010 Dec; 43(3):321-326. PubMed ID: 21036667
    [Abstract] [Full Text] [Related]

  • 32. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I, Cepulić BG, Mazić S.
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [Abstract] [Full Text] [Related]

  • 33. Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients.
    Mathew S, Adel N, Rice RD, Panageas K, Duck ET, Comenzo RL, Kewalramani T, Nimer SD.
    Bone Marrow Transplant; 2010 Oct; 45(10):1522-7. PubMed ID: 20062102
    [Abstract] [Full Text] [Related]

  • 34. Utilization study of filgrastim (Neutromax) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patients.
    Ferro HH, Juni M, Bello R, Vidal A, Diez RA, Pavlovsky S.
    Transfus Apher Sci; 2009 Oct; 41(2):87-93. PubMed ID: 19699152
    [Abstract] [Full Text] [Related]

  • 35. [Haematopoietic stem cell mobilization in patients with multiple myeloma--comparison of 3 variations of the stimulating regime].
    Krejcí M, Hájek R, Korístek Z, Krivanová A, Navrátil M, Adam Z.
    Vnitr Lek; 2000 Aug; 46(8):439-43. PubMed ID: 11048505
    [Abstract] [Full Text] [Related]

  • 36. Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.
    Ng R, Green MD.
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):585-90. PubMed ID: 16111460
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.
    Kim MG, Han N, Lee EK, Kim T.
    Bone Marrow Transplant; 2015 Apr; 50(4):523-30. PubMed ID: 25581410
    [Abstract] [Full Text] [Related]

  • 39. Improved granulocyte colony-stimulating factor mobilization of hemopoietic progenitors using cytokine combinations in primates.
    Larsen SR, Chng K, Battah F, Martiniello-Wilks R, Rasko JE.
    Stem Cells; 2008 Nov; 26(11):2974-80. PubMed ID: 18719223
    [Abstract] [Full Text] [Related]

  • 40. Neutrophil growth factors.
    Crawford J.
    Curr Hematol Rep; 2002 Nov; 1(2):95-102. PubMed ID: 12901130
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.